Similar Papers

Paper Title
Journal
Date
Author
Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies
Andi K Cani ... Rajesh C Rao
Modern Pathology | VOL. 29
Andi K Cani, et. al.Andi K Cani ... Rajesh C Rao
01 Jul 2016
Overexpression of miR-222-3p Promotes the Proliferation and Inhibits the Apoptosis of Diffuse Large B-Cell Lymphoma Cells via Suppressing PPP2R2A.
Shanshan Sun ... Hui Wang
Technology in Cancer Research & Treatment | VOL. 18
Shanshan Sun, et. al.Shanshan Sun ... Hui Wang
01 Jan 2019
CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling
Paolo F Caimi ... Joseph Boni
Blood | VOL. 140
Paolo F Caimi, et. al.Paolo F Caimi ... Joseph Boni
15 Nov 2022
Comparison of pathological features and prognosis between orbital and systemic diffuse large B cell lymphoma
...
Chinese Journal of Experimental Ophthalmology | VOL. 32
, et. al. ...
10 Oct 2014
View more papers

More From: Clinical Lymphoma, Myeloma and Leukemia

Paper Title
Journal
Date
Author
SOHO State of the Art Updates and Next Questions | Venetoclax + Obinutuzumab Therapy in Chronic Lymphocytic Leukemia
Andrew H Lipsky ... Nicole Lamanna
Clinical Lymphoma, Myeloma and Leukemia | VOL. -
Andrew H Lipsky, et. al.Andrew H Lipsky ... Nicole Lamanna
01 Dec 2024
Table of Contents
-
Clinical Lymphoma, Myeloma and Leukemia | VOL. 24
--
01 Dec 2024
A phase I study of romidepsin in combination with gemcitabine, oxaliplatin, and dexamethasone in patients with relapsed or refractory aggressive lymphomas enriched for T-cell lymphomas.
Nicole Foley ... Neha Mehta-Shah
Clinical Lymphoma, Myeloma and Leukemia | VOL. -
Nicole Foley, et. al.Nicole Foley ... Neha Mehta-Shah
01 Dec 2024
Editorial Board
-
Clinical Lymphoma, Myeloma and Leukemia | VOL. 24
--
01 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.